Hanmi Pharm enters 3.2 trillion won licensing agreement with Genentech for obesity drug candidate

Hanmi Pharmaceutical has secured a licensing deal with Roche subsidiary Genentech to develop and commercialize a novel obesity drug candidate. The agreement, valued at approximately 3.2 trillion won, marks a significant expansion of Hanmi's pipeline in the metabolic disease sector and strengthens its partnership with a major global pharmaceutical entity.